Protocol of comparison of the effects of single plasma exchange and double filtration plasmapheresis on peripheral lymphocyte phenotypes in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: a monocentric prospective study with single-case experimental design

O Moranne, I M Ion, R Cezar, Z Messikh, C Prelipcean, S Chkair, E Thouvenot, Tu Anh Tran, P Corbeau, T Chevallier, O Moranne, I M Ion, R Cezar, Z Messikh, C Prelipcean, S Chkair, E Thouvenot, Tu Anh Tran, P Corbeau, T Chevallier

Abstract

Background: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a rare disorder affecting young adults, causes gradual weakness of the limbs, areflexia and impaired sensory function. New CIDP phenotypes without pathogenic antibodies but with modified cell profiles have been described. Treatments include corticotherapy, intravenous immunoglobulins, and plasmapheresis but the latter's action mechanisms remain unclear. Plasmapheresis supposedly removes toxic agents like antibodies from plasma but it is uncertain whether it has an immune-modulating effect. Also, the refining mechanisms of the two main plasmapheresis techniques-single plasma exchange and double filtration plasmapheresis (DFPP) - are different and unclear. This study aims to compare the evolution of peripheral lymphocyte profiles in patients with CIDP according to their treatment (single centrifugation plasmapheresis or DFPP) to better grasp the action mechanisms of both techniques.

Method: In this proof-of-concept, monocentric, prospective, Single-Case Experimental Design study, 5 patients are evaluated by alternating their treatment type (single plasma exchange or DFPP) for 6 courses of treatment after randomization to their first treatment type. Each course of treatment lasts 2-4 weeks. For single plasma exchange, 60 ml/kg plasma will be removed from the patient and replaced with albumin solutes, with a centrifugation method to avoid the immunological reaction caused by the membrane used with the filtration method. For DFPP, 60 ml/kg plasma will be removed from the patient with a plasma separator membrane, then processed via a fractionator membrane to remove molecules of a greater size than albumin before returning it to the patient. This technique requires no substitution solutes, only 20 g of albumin to replace what would normally be lost during a session. The primary outcome is the difference between the two plasmapheresis techniques in the variation of the TH1/TH17 ratio over the period D0H0-D0H3 and D0H0-D7. Secondary outcomes include the variation in lymphocyte subpopulations at each session and between therapeutic plasmapheresis techniques, the clinical evolution, tolerance and cost of treatments.

Discussion: Understanding the action mechanisms of single plasma exchange and DFPP will help us to offer the right treatment to each patient with CIPD according to efficacy, tolerance and cost.

Trial registration: ClinicalTrials.gov under the no. NCT04742374 and date of registration 10 December 2020.

Keywords: CIDP; DFPP; Plasma exchange.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study design

References

    1. Broers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2019;52(3–4):161–172. doi: 10.1159/000494291.
    1. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripher: EFNS/PNS CIDP guideline - first revision. Eur J Neurol. 2010;17(3):356–363. doi: 10.1111/j.1468-1331.2009.02930.x.
    1. Vallat J-M, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol. 2010;9(4):402–412. doi: 10.1016/S1474-4422(10)70041-7.
    1. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507–517. doi: 10.1038/nrneurol.2011.121.
    1. Chi LJ, Xu WH, Zhang ZW, Huang HT, Zhang LM, Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(4):345–356. doi: 10.1111/j.1529-8027.2010.00294.x.
    1. Oaklander AL, Gimigliano F. Are the treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) effective and safe? - A Cochrane Overview summary with commentary. NeuroRehabilitation. 2019;44(4):609–612. doi: 10.3233/NRE-189007.
    1. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue: Therapeutic Apheresis-Guidelines 2016. J Clin Apheresis. 2016;31(3):149–338. doi: 10.1002/jca.21470.
    1. Zhang L, Liu J, Wang H, et al. Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action. J Clin Neurosci Off J Neurosurg Soc Australas. 2014;21(9):1570–1574. doi: 10.1016/j.jocn.2013.11.046.
    1. Rodríguez Y, Vatti N, Ramírez-Santana C, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019;102:8–37. doi: 10.1016/j.jaut.2019.04.021.
    1. Chaigne B, Mouthon L. Mechanisms of action of intravenous immunoglobulin. Transfus Apher Sci. 2017;56(1):45–49. doi: 10.1016/j.transci.2016.12.017.
    1. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–351. doi: 10.1111/bjh.12629.
    1. Maddur MS, Rabin M, Hegde P, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients. Immunol Res. 2014;60(2–3):320–329. doi: 10.1007/s12026-014-8580-6.
    1. Yeh J-H, Wang S-H, Chien P-J, Shih C-M, Chiu H-C. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol. 2009;16(12):1318–1322. doi: 10.1111/j.1468-1331.2009.02729.x.
    1. de Back DZ, Neyrinck MM, Vrielink H. Therapeutic plasma apheresis: Expertise and indications. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2019;58(3):254–257. doi: 10.1016/j.transci.2019.04.008.
    1. Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematol Am Soc Hematol Educ Program. 2012;2012:7–12. doi: 10.1182/asheducation-2012.1.7.
    1. Siami GA, Siami FS. Membrane Plasmapheresis in the United States: A Review Over the Last 20 Years. Ther Apher Dial. 2001;5(4):315–320. doi: 10.1046/j.1526-0968.2001.00316.x.
    1. M Oczko-Walker G Manousakis S Wang JS Malter AJ Waclawik 2010 Plasma Exchange After Initial Intravenous Immunoglobulin Treatment in Guillain-Barré Syndrome: Critical Reassessment of Effectiveness and Cost-Efficiency: J Clin Neuromuscul Dis 12 2 55 61 10.1097/CND.0b013e3181f3dbbf
    1. Kumazawa K, Yuasa N, Mitsuma T, Nagamatsu M, Sobue G. Double filtration plasmapheresis (DFPP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Rinsho Shinkeigaku. 1998;38(8):719–723.
    1. Padmanabhan A, Connelly‐Smith L , Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apheresis. 2019;34(3):171–354. doi: 10.1002/jca.21705.
    1. Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. 2014;18(1):41–49. doi: 10.1007/s10157-013-0838-0.
    1. Drummond MF, ed. Methods for the Economic Evaluation of Health Care Programmes. 3. ed., reprint. Oxford Univ. Press; 2007.
    1. Mauskopf JA, Sullivan SD,, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices— Budget Impact Analysis. Value in Health. 2007:336–347.
    1. Choices in methods for economic evaluation . Validated by the CEESP on 6 April 2020. Haute Aut Santé: Published online; 2012.
    1. Ganz JB, Ayres KM. Methodological standards in single-case experimental design: Raising the bar. Res Dev Disabil. 2018;79:3–9. doi: 10.1016/j.ridd.2018.03.003.
    1. Smith JD. Single-case experimental designs: A systematic review of published research and current standards. Psychol Methods. 2012;17(4):510–550. doi: 10.1037/a0029312.
    1. Dallery J, Cassidy RN, Raiff BR. Single-Case Experimental Designs to Evaluate Novel Technology-Based Health Interventions. J Med Internet Res. 2013;15(2):e22. doi: 10.2196/jmir.2227.
    1. Kazdin AE. Single-Case Research Designs: Methods for Clinical and Applied Settings. 2. Press: Oxford Univ; 2011.
    1. Krasny-Pacini A, Evans J. Single-case experimental designs to assess intervention effectiveness in rehabilitation: A practical guide. Ann Phys Rehabil Med. 2018;61(3):164–179. doi: 10.1016/j.rehab.2017.12.002.
    1. Tate RL, Perdices M, Rosenkoetter U, et al. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement. Phys Ther. 2016;96(7):e1–e10. doi: 10.2522/ptj.2016.96.7.e1.
    1. Kaneko Y. Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation. Science. 2006;313(5787):670–673. doi: 10.1126/science.1129594.
    1. Basta M. Modulation of complement-mediated immune damage by intravenous immune globulin. Clin Exp Immunol. 1996;104(Suppl 1):21–25.
    1. Gelfand EW. Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases. N Engl J Med. 2012;367(21):2015–2025. doi: 10.1056/NEJMra1009433.
    1. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101(2):758–765. doi: 10.1182/blood-2002-05-1447.
    1. Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci. 2015;112(18):E2385–E2394. doi: 10.1073/pnas.1505292112.
    1. Maddur MS, Othy S, Hegde P, et al. Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells. J Clin Immunol. 2010;30(S1):4–8. doi: 10.1007/s10875-010-9394-5.
    1. João C, Ogle BM, Gay-Rabinstein C, Platt JL, Cascalho M. B Cell-Dependent TCR Diversification. J Immunol. 2004;172(8):4709–4716. doi: 10.4049/jimmunol.172.8.4709.
    1. Barth H, Klein R, Berg PA, Wiedenmann B, Hopf U, Berg T. Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection. Hepatogastroenterology. 2003;50(49):201–206.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅